切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2019, Vol. 07 ›› Issue (02) : 168 -171. doi: 10.3877/cma.j.issn.2095-5782.2019.02.016

所属专题: 文献

综述

小儿实体肿瘤介入治疗进展
王斌1,()   
  1. 1. 300350 天津市环湖医院肿瘤介入科、天津市脑血管与神经变性重点实验室
  • 收稿日期:2019-03-16 出版日期:2019-05-01
  • 通信作者: 王斌

Research progress on interventional therapy for treatment of pediatric tumor

Bin Wang1,()   

  1. 1. Department of Interventional Radiology, Tianjin Huanhu Hospital, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin 300350, China
  • Received:2019-03-16 Published:2019-05-01
  • Corresponding author: Bin Wang
  • About author:
    Corresponding author: Wang Bin, Email:
引用本文:

王斌. 小儿实体肿瘤介入治疗进展[J]. 中华介入放射学电子杂志, 2019, 07(02): 168-171.

Bin Wang. Research progress on interventional therapy for treatment of pediatric tumor[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2019, 07(02): 168-171.

小儿肿瘤近年来发病率越来越高,但小儿实体肿瘤的相关研究明显滞后。小儿实体肿瘤以神经系统肿瘤的比例较高,其他实体肿瘤主要为骨肿瘤、肾脏、肝脏等相关肿瘤。神经系统的介入治疗仍未广泛应用,接受介入治疗比例最高的肿瘤为肝细胞癌。介入治疗能够抑制癌组织的生长,联合手术治疗能够明显提高患者的生存期。介入治疗为不能接受手术治疗的患者提供了新的治疗思路,让更多的患者有了更多治疗选择。但是介入治疗在小儿肿瘤的应用中仍有许多问题需要我们在临床工作中继续努力,不断创新。

In recent years, the incidence of pediatric tumors is increasing, but the research on pediatric solid tumors lags behind. Neurological tumors were the most common solid tumors in children, while other solid tumors were mainly bone tumors, kidney tumors and liver tumors. Interventional therapy for the nervous system is still not widely used. Hepatocellular carcinoma (HCC) was the most frequently treated tumor. Interventional therapy can inhibit the growth of cancer tissue, and combined surgery can significantly improve the survival of patients. More importantly, interventional therapy provides new treatment ideas for patients who cannot receive surgical treatment and more patients have more treatment options. However, there are still many problems in the application of interventional therapy in pediatric tumors, which needs our continuous efforts and innovations in clinical work.

[1]
Smith MA, Seibel NL, AltekruseSF,et al. Outcomes for children and adolescents with cancer:challenges for the twenty-first century[J]. J Clin Oncol,2010,28(15):2625-2634.
[2]
Friedman DL, Whitton J, Leisenring W,et al. Subsequent neoplasms in 5-year survivors of childhood cancer:the Childhood Cancer Survivor Study[J]. J Natl Cancer Inst,2010,102(14):1083-1095.
[3]
Henderson T, Robison L, Mertens A,et al. Sarcomas as a subsequent malignancy in survivors of pediatric malignancy:The Childhood Cancer Survivor Study[J]. JCO,2005,23(16_suppl):8515.
[4]
deLarco JE, Todaro GJ. Growth factors from murine sarcoma virus-transformed cells[J]. Proc Natl AcadSci USA,1978,75(8):4001-4005.
[5]
Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004[J]. Cancer,2009,115(7):1531-1543.
[6]
Liu SJ, Zheng LY, Aweya JJ,et al. Litopenaeus vannamei hemocyanin exhibits antitumor activity in S180 mouse model in vivo[J]. PLoS One,2017,12(8):e0183783.
[7]
Blau O. Molecular investigation of Ewing sarcoma:about detecting translocations[J]. EMBO Mol Med,2012,4(6):449-450.
[8]
Northcott PA, Korshunov A, Witt H,et al. Medulloblastoma comprises four distinct molecular variants[J]. J Clin Oncol,2011,29(11):1408-1414.
[9]
Stewart LA. Chemotherapy in adult high-grade glioma:A systematic review and meta-analysis of individual patient data from 12 randomisedtrials[J]. Lancet,2002,359(9311):1011-1018.
[10]
雷彦明,旦增罗布,边巴扎西,等.西藏高原地区MDT后全麻下介入治疗儿童肝母细胞瘤一例[J].中华介入放射学电子杂志,2016,4(2):124-125.
[11]
Chen YF, Li YW, Sheih CP,et al. Renal cell carcinoma:unusual pediatric renal tumors[J]. J Formos Med Assoc,1999,98(2):118-121.
[12]
Reardon DA, Quinn JA, Vredenburgh J,et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma[J]. Cancer,2005,103(2):329-338.
[13]
Quinn JA, Jiang SX, Reardon DA,et al. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma[J]. Cancer,2009,115(13):2964-2970.
[14]
单鸿.临床介入诊疗学[M].广州:广东科技出版社,1997:47-50.
[15]
Seki A, Hori S. Switching the loaded agent from epirubicin to cisplatin:salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol,2012,35(3):555-562.
[16]
Shirota Y, Yamashita T, Terasaki S,et al. Treatment with subsegmentaltranscatheter arterial embolization for hepatocellular carcinoma:prognosis,recurrence,and effect on liver function[M]//Shirota Y,Yamashita T,Terasaki S,et al. eds. Progress in Hepatocellular Carcinoma Treatment. Tokyo:Springer Japan,2000:35-39.
[17]
Itsubo M, Koike K, Tsuno S,et al. Subsegmental transcatheter arterial embolization for small hepatocellular carcinoma[J]. Hepatogastroenterology,2002,49(45):735-739.
[18]
Hayashi K, Ina H, Tezuka M,et al. Local therapeutic results of computed tomography-guided transcatheterarterial chemoembolization for hepatocellular carcinoma:results of 265 tumors in 79 patients[J]. Cardiovasc Intervent Radiol,2007,30(6):1144-1155.
[19]
Phillips WT, BaoA, Brenner AJ,et al. Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles[J]. Adv Drug Deliv Rev,2014,76:39-59.
[20]
Liu YM, Qin H, Wang CB,et al. Comparison of therapeutic effectiveness of combined interventional therapy for 1126 cases of primary liver cancer[J]. World J Gastroenterol,2006,12(31):5060-5063.
[21]
吴汉平,冯敢生.肝癌介入治疗的现状与展望[J].临床放射学杂志,2005,24(3):273-276.
[22]
祝秀丹.儿童肿瘤治疗现状[J].中国处方药,2005,3(2):24-28.
[23]
郝向东,朱铭.小儿肾胚胎瘤术前介入治疗16例[J].临床小儿外科杂志,2007,6(4):47-48.
[24]
郭芳,成守礼.小儿肾胚胎瘤的外科诊治回顾[J].山西医学院学报,1994(S1):76-77.
[25]
Li JP, Chu JP, Oh P,et al. Characterizing clinicopathological findings of transarterial chemoembolization for Wilms tumor [J]. J Urol,2010,183(3):1138-1144.
[26]
Ogita S, Tokiwa K, Taniguchi H,et al. Intraarterial chemotherapy with lipid contrast medium for hepatic malignancies in infants[J]. Cancer,1987,60(12):2886-2890.
[27]
Kloeckner R, Weinmann A, Prinz F,et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma[J]. BMC Cancer,2015,15:465.
[28]
Izaki K, Sugimoto K, Sugimura K,et al. Transcatheterarterial embolization for advanced tumor thrombus with marked arterioportal or arteriovenous shunt complicating hepatocellular carcinoma[J]. Radiat Med,2004,22(3):155-162.
[29]
Yamamoto T, Kawarada Y, Yano T,et al. Spontaneous rupture of hemangioma of the liver:treatment with transcatheter hepatic arterial embolization[J]. Am J Gastroenterol,1991,86(11):1645-1649.
[30]
Tanaka K, Nakamura S, Numata K,et al. The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis[J]. Cancer,1998,82(1):78-85.
[31]
贾科峰,于长路,孙诚,等.不同血供类型肝血管瘤的介入治疗效果长期随访评价[J].中华介入放射学电子杂志,2018,6(1):27-31.
[32]
刘方,张俊义,邢纪中,等.选择性动脉灌注化疗治疗小儿卵巢恶性生殖细胞瘤[J].中华小儿外科杂志,2004,25(1):87-88.
[33]
李旭彤,吴宝音,李伟男,等.介入栓塞治疗不同体积肝血管瘤的临床疗效及血流动力学特征[J].肝脏,2016,21(6):485-488.
[34]
范丽娟.膀胱肿瘤介入治疗的护理[J].中国保健营养旬刊,2013,9:5280-5281.
[35]
罗鹏飞,陈晓明,符力.肝癌介入治疗的有关问题及处理[J].中华肝脏病杂志,2002,10(3):216.
[36]
王执民.中晚期肝癌介入治疗中应该注意的几个问题[J].介入放射学杂志,2004,13(6):481-482.
[1] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[2] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[3] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[4] 李斌奎. 不可切除肝内胆管细胞癌的转化治疗[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 511-516.
[5] 刘中百, 任勇军. 肝细胞癌的介入治疗现状及进展[J]. 中华消化病与影像杂志(电子版), 2023, 13(02): 111-115.
[6] 周斌, 刘新献. 术前TACE对提高儿童肝母细胞瘤长期生存率的影响[J]. 中华介入放射学电子杂志, 2023, 11(04): 314-317.
[7] 吴雅琴, 莫伟, 向华, 李琴, 李玉莲, 周碧芳. 肝癌患者介入术后股动脉穿刺处出血的研究进展[J]. 中华介入放射学电子杂志, 2023, 11(04): 352-356.
[8] 李世凯, 梁佳, 何艳艳, 于毅, 李天晓, 常金龙, 贺迎坤. 兔颈动脉粥样硬化性狭窄模型在介入治疗的应用进展[J]. 中华介入放射学电子杂志, 2023, 11(04): 357-362.
[9] 张德伟, 雷毅, 江哲宇, 王黎洲, 许国辉, 周石. 杂交手术治疗下肢深静脉血栓合并下肢急性动脉血栓一例[J]. 中华介入放射学电子杂志, 2023, 11(04): 380-384.
[10] 葛校永, 李亚华, 李宗明, 周子鹤, 吴昆鹏, 李一帆, 韩新巍, 任克伟. 新型温敏性水凝胶在经导管动脉化疗栓塞中的应用进展[J]. 中华介入放射学电子杂志, 2023, 11(03): 268-274.
[11] 林加文, 印于, 杨俊, 朱晓黎, 王万胜. 肝动门静脉瘘合并腹水一例[J]. 中华介入放射学电子杂志, 2023, 11(03): 289-291.
[12] 吴雅琴, 莫伟, 向华, 李琴, 李兰. 肝癌患者介入治疗穿刺处出血影响因素的真实世界研究[J]. 中华介入放射学电子杂志, 2023, 11(02): 117-122.
[13] 陈丹丹, 潘文志, 陈莎莎, 张源, 张晓春, 李明飞, 周达新, 葛均波. 结构性心脏病年度报告2022[J]. 中华心脏与心律电子杂志, 2023, 11(03): 129-140.
[14] 孙相利, 许真真. 经皮冠状动脉旋磨术在冠状动脉重度钙化病变介入治疗中的应用[J]. 中华老年病研究电子杂志, 2023, 10(02): 33-36.
[15] 姜新鹏, 李晓明, 杨航, 宫一宸, 傅元豪, 傅瑜, 张喆. 单纯经胸超声心动图引导卵圆孔未闭封堵术早期安全性及有效性分析[J]. 中华脑血管病杂志(电子版), 2023, 17(04): 320-324.
阅读次数
全文


摘要